Bispecific monoclonal antibody - Wikipedia
A bispecific monoclonal antibody (BsMAb, BsAb) is an artificial protein that can simultaneously bind to two different types of antigen or two different epitopes on the same antigen. [1] Naturally occurring antibodies typically only target one antigen.
The present and future of bispecific antibodies for cancer therapy
Mar 6, 2024 · Bispecific antibodies (bsAbs) have gained major interest in the past decade, given their unique and versatile modes of action (MoA). The approval of nine bsAbs for cancer therapy in the past 3...
Bispecific Antibodies: An Area of Research and Clinical Applications
Researchers compared key quality attributes and biological activities of BsAbs with different molecular formats and analyzed how the antibodies stopped tumor growth in the cellular and animal...
Bispecific Antibodies: From Research to Clinical Application
Bispecific antibodies (BsAbs) are antibodies with two binding sites directed at two different antigens or two different epitopes on the same antigen. The clinical therapeutic effects of BsAbs are superior to those of monoclonal antibodies (MoAbs), ...
Current landscape and future directions of bispecific antibodies …
Compared to monoclonal antibodies targeting CD16A, the ADCC potency is increased by more than 100 times using the NKp30 bispecific platform, which also maintains activity when CD16A is downregulated. Bispecific antibodies against NK redirection are still mainly used to treat hematological tumors.
Bispecific antibodies: design, therapy, perspectives - PMC
Antibodies (Abs) containing two different antigen-binding sites in one molecule are called bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal BsAbs were generated in the 1980s by hybridoma technology, and the ...
Bispecific and multispecific antibodies in oncology ... - Nature
May 31, 2024 · Non-IgG-like or fragment-based bispecific antibodies feature the variable light chain (VL) and variable heavy chain (VH) domains, or Fab units, from two monoclonal antibodies without an Fc...
Bispecific antibodies: advancing precision oncology - Cell Press
Aug 29, 2024 · Bispecific antibodies (bsAbs) offer a novel approach to anticancer therapy by targeting different antigens via a range of mechanisms of action. Manipulating bsAb structures allows generation of multiple formats to optimize molecular function for specific clinical contexts.
Bispecific Antibodies: From Research to Clinical Application
May 5, 2021 · Bispecific antibodies (BsAbs) are antibodies with two binding sites directed at two different antigens or two different epitopes on the same antigen. The clinical therapeutic effects of BsAbs are superior to those of monoclonal antibodies (MoAbs), with broad applications for tumor immunotherapy as well as for the treatment of other diseases.
Bispecific Antibody - an overview | ScienceDirect Topics
AFM13 is a bispecific monoclonal antibody construct that binds to the isoform CD16A on the surface of natural killer cells and CD30 positive malignant cells, thus accomplishing an efficient antitumor effect via the activation of natural killer cells.